FDA advises COVID vaccine makers to produce updated shots against XBB1.5
Wachiwit/iStock via Getty Images                 
The US FDA is advising makers of COVID-19 vaccines that updated shots that will be administered in the fall should be monovalent ones against the Omicron XBB1.5 variant.

The decision comes a day after an US FDA advisory panel unanimously recommended updated jabs against XBB variants.
XBB1.5 is currently the most prevalent variant in the U.S., responsible for ~40% of cases.
At Thursday's advisory committee meeting, Pfizer (NYSE:PFE), Moderna (NASDAQ:MRNA), and Novavax (NASDAQ:NVAX) made presentations.